Le Lézard
Classified in: Health
Subjects: NPT, TDS, SCZ

AngelaCARES to have 8th Annual Senior Citizens Prom

JERSEY CITY, N.J., April 23, 2019 /PRNewswire-PRWeb/ -- Providing an opportunity for seniors to get out of the house, socialize with others, and enjoy themselves is essential to helping them maintain a healthy lifestyle and live life to the fullest. Unfortunately, as seniors age, the lack of socialization comes into play.

The two most pressing obstructions seniors are met with when trying to maintain a healthy social life, are availability and accessibility. AngelaCARES Inc. has and continues to challenge these obstructions by hosting our 8th Annual Senior Citizen Prom (free to Hudson County Seniors) to take place at Saint Peter's University Mac Mahon Student Union Building, 47 Glenwood Avenue, Jersey City, NJ, Friday, May 24, 2019 from 6:00 pm until 10:00 pm.

The world we live in today provides us with various ways to extend our lives, from the food we eat, to the growth of science. They say 60 is the new 50 and humans are living longer than they used to.

Rush University Medical Center states: "Social activity has long been recognized as an essential component of healthy aging, but now we have strong evidence that it is also related to better everyday functioning and less disability in old age," said lead researcher Bryan James, PhD, postdoctoral fellow in the epidemiology of aging and dementia in the Rush Alzheimer's Disease Center. "The findings are exciting because social activity is potentially a risk factor that can be modified to help older adults avoid the burdens of disability."

Please call us today at 201-706-2884 or email us at mailbox(at)angelacares.org to find out more about how you can help.

Thank you,
Team AngelaCARES

AngelaCARES, Inc.TM 501(c)(3) nonprofit organization headquartered in Jersey City, New Jersey. Our mission is to serve as an advocate and support system for senior citizens, their caregivers, and a mentor to the youth by educating and empowering them to volunteer. We are committed to strengthening communities by enhancing the quality of life through the generations.



These press releases may also interest you

at 11:50
New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT) over 12 months in high-risk patients...

at 11:05
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreased risk of hospitalisation for heart failure and a...

at 11:00
The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single ventricle heart defects. A study leader says the...

at 10:50
AstraZeneca today announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that FARXIGA (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure (HF), defined as...

at 10:50
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated with a decreased risk of hospitalization for heart...

at 10:45
Mezzion Pharma Co. Ltd. (140410: KOSDAQ) today announces the presentation of data from its pivotal clinical trial for its new orphan drug for the treatment of adolescents with single ventricle heart disease. Dr. David...

News published on 23 april 2019 at 09:00 and distributed by: